Horseshoe crabs are harvested for their blue blood used in pharmaceutical testing. Understanding the welfare and conservation implications helps direct advocacy for better alternatives.
Horseshoe crab biomedical use raises both conservation and welfare concerns. The blood collection process involves capture, transport, bleeding, and return to the ocean - a process that causes measurable physiological stress and 15-30% mortality depending on conditions. Crabs that survive release may show reduced activity and altered behavior suggesting ongoing physiological impacts. The welfare case for transitioning to rFC, a validated synthetic alternative, is strong: it eliminates animal use entirely while providing equivalent or superior contamination detection. Industry resistance to transition has slowed adoption despite scientific validation. The welfare and conservation costs of continuing horseshoe crab blood harvesting are real and avoidable given the existence of an effective alternative.